Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma.
Silva Paula
Jayter
J
Jorge
Rodrigo
R
Alves Costa
Rogério
R
Rodrigues
Maria de Lourdes V
Mde L
Scott
Ingrid U
IU
D000368:Aged; D000869:Anterior Eye Segment / Q000098:blood supply*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003930:Diabetic Retinopathy / Q000150:complications; D005260:Female; D015355:Glaucoma, Neovascular / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure; D007498:Iris / Q000098:blood supply*; D009389:Neovascularization, Pathologic / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology; D014792:Visual Acuity; D014822:Vitreous Body
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab